Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – OBTAINING DRUG MARKETING AUTHORISATION OF AZILSARTAN TABLETS

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Lee's Pharmaceutical Holdings Limited (the "**Company**" or "**Lee's Pharm**", together with its subsidiaries as the "**Group**") on a voluntary basis.

The Board of the Company is pleased to announce that on 20 September 2022, the marketing authorisation for generics of Azilsartan tablets (specification: 20mg) developed and manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited ("**Zhaoke Guangzhou**"), a wholly-owned subsidiary of the Company, has been obtained from the National Medical Products Administration of the People's Republic of China ("**NMPA**") (國藥准字H20223680). The drug has been approved to treat hypertension.

The original drug was developed by Takeda Pharmaceutical Company Limited in Japan and was granted marketing authorisation in Japan in January 2012. For the purpose of demonstrating the consistency in the quality and efficacy of the generic drug and the original product, Zhaoke Guangzhou commenced a clinical trial for the bioequivalence with the original drug in 2019. The trial results showed that the original and generic drugs are bioequivalent and have similar performance in terms of safety. The NMPA has recognised such results and approved the marketing of the generic drug.

ABOUT AZILSARTAN TABLETS

An Azilsartan tablet is a selective long-acting antagonist for angiotensin II type 1 receptor ("**AT1 Receptor**"). When binding with angiotensin II type 1 receptor, it has the effects of blood vessel dilation and antihypertension by inhibiting the artery contraction of angiotensin type 2 and lowering the resistance of peripheral arteries.

* *For identification purpose only*

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. Since early 2022, Lee's Pharm and its subsidiaries have obtained the marketing authorisation of 7 products in total in Mainland China, namely Lidocaine Hydrochloride Powder Needle-free Intradermal Injection System, nitric oxide for inhalation, Treprostinil Injection (20ml:50mg), Procarbazine Hydrochloride Capsules, Riluzole Oral Suspension, Nadroparin Calcium Injection and Azilsartan tablets. More information available at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 29 September 2022

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors of the Company, Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors of the Company.